tiprankstipranks
Trending News
More News >
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR

Monopar Therapeutics Inc (MNPR) AI Stock Analysis

Compare
521 Followers

Top Page

MN

Monopar Therapeutics Inc

(NASDAQ:MNPR)

48Neutral
Monopar’s overall stock score is primarily affected by its financial performance challenges, such as negative cash flows and lack of revenue. However, the strong cash position and debt-free status provide some stability. The technical indicators show neutral market sentiment, while the new CFO appointment brings a positive strategic outlook. The valuation reflects typical biotech hurdles with a negative P/E ratio.
Positive Factors
Drug Development
ALXN-1840 is considered a derisked drug for the treatment of Wilson's disease and a commercial launch would provide revenue to fund the development of their radiopharmaceutical.
Market Potential
The total addressable market for ALXN1840 could reach $420M in the U.S. alone, based on an estimate of 10,000-12,000 WD patients in the U.S.
Strategic Partnerships
Monopar Therapeutics announced a strategic agreement with Alexion, AstraZeneca Rare Disease, for the exclusive worldwide in-licensing of ALXN-1840 for the treatment of Wilson's disease.
Negative Factors
Financial Performance
The company reported no revenues, in line with consensus estimates, and a net loss of $4.11 per share, compared to consensus estimated net loss of $1.29 per share.
Investor Focus
Investors are expected to be more focused on later-stage ALXN-1840 and anticipate incremental updates from MNPR-101-Lu to have a muted impact on share price in the near term.
Regulatory Challenges
Providing proof of fecal excretion of copper might require an additional study, posing a potential regulatory hurdle for ALXN1840's approval.

Monopar Therapeutics Inc (MNPR) vs. S&P 500 (SPY)

Monopar Therapeutics Inc Business Overview & Revenue Model

Company DescriptionMonopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for cancer patients. The company operates within the biotechnology and pharmaceuticals sectors, concentrating its efforts on advancing a pipeline of proprietary oncology drug candidates. Its core product candidates include therapies targeting severe side effects of chemotherapy and novel approaches to treat various types of cancer.
How the Company Makes MoneyMonopar Therapeutics Inc. primarily makes money through the development and potential commercialization of its drug candidates. The company is in a clinical-stage, meaning its revenue model is largely oriented towards the successful advancement of its drug pipeline through clinical trials. Revenue streams may include potential milestone payments and royalties from partnerships or licensing agreements with larger pharmaceutical companies. Additionally, Monopar may receive government grants or funding from non-profit organizations to support its research and development efforts. The company's financial success is heavily reliant on the clinical and regulatory success of its product candidates, as well as its ability to establish strategic collaborations.

Monopar Therapeutics Inc Financial Statement Overview

Summary
Monopar Therapeutics faces typical early-stage biotech challenges with no revenue and ongoing losses. Despite a strong cash position and no debt, the reliance on external financing and negative cash flows pose risks. The focus on transitioning from R&D to commercialization is crucial for long-term financial sustainability.
Income Statement
Monopar Therapeutics Inc has shown consistent negative EBIT and net income figures over the years, reflecting ongoing operational challenges. The company has not generated any revenue, which is expected in early-stage biotech firms but poses significant risks for sustainability without revenue growth. The lack of gross profit margin and net profit margin metrics further underscores the absence of sales revenue. The substantial increase in net loss in 2024 signals heightened financial strain.
Balance Sheet
40
The balance sheet reveals a strong cash position with no debt, which is a positive indicator of financial flexibility. The equity ratio remains healthy, suggesting that the company is well-capitalized. However, the company's assets and equity have become more volatile, as evidenced by the large equity increase in 2024, potentially from financing activities. The absence of revenue generation remains a challenge for long-term viability.
Cash Flow
Operating cash flows have been negative consistently, indicating cash outflows from core operations. The significant increase in financing cash flows in 2024 suggests reliance on external funding for cash needs. Free cash flow remains negative, which is typical for biotech firms in development stages but highlights the need for successful product development and commercialization to improve cash flow health.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.000.000.000.000.00
EBIT
-8.83M-10.54M-9.13M-6.51M-4.32M
EBITDA
429.04K0.000.000.000.00
Net Income Common Stockholders
-8.40M-10.49M-9.08M-6.22M-4.13M
Balance SheetCash, Cash Equivalents and Short-Term Investments
7.27M13.12M20.30M16.74M13.21M
Total Assets
7.35M13.23M20.52M16.87M13.35M
Total Debt
0.008.41K0.000.000.00
Net Debt
-7.27M-8.18M-20.30M-16.74M-13.21M
Total Liabilities
1.76M3.14M1.58M1.18M724.16K
Stockholders Equity
5.59M10.09M18.94M15.69M12.63M
Cash FlowFree Cash Flow
-7.86M-7.23M-7.32M-4.66M-3.02M
Operating Cash Flow
-7.86M-7.23M-7.32M-4.66M-3.02M
Investing Cash Flow
4.93M-4.92M0.000.000.00
Financing Cash Flow
2.03M32.87K10.88M8.18M9.35M

Monopar Therapeutics Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price39.10
Price Trends
50DMA
36.55
Positive
100DMA
35.28
Positive
200DMA
22.17
Positive
Market Momentum
MACD
1.42
Positive
RSI
55.05
Neutral
STOCH
22.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Positive. The current price of 39.1 is below the 20-day moving average (MA) of 40.55, above the 50-day MA of 36.55, and above the 200-day MA of 22.17, indicating a bullish trend. The MACD of 1.42 indicates Positive momentum. The RSI at 55.05 is Neutral, neither overbought nor oversold. The STOCH value of 22.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MNPR.

Monopar Therapeutics Inc Risk Analysis

Monopar Therapeutics Inc disclosed 79 risk factors in its most recent earnings report. Monopar Therapeutics Inc reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Monopar Therapeutics Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$233.70M-36.07%-7.93%
52
Neutral
$5.23B3.70-41.86%2.84%16.58%-0.16%
48
Neutral
$237.05M-51.42%-35.23%
46
Neutral
$253.37M-23.68%14.60%
43
Neutral
$275.39M-16.20%498.72%49.92%
43
Neutral
$247.11M-222.36%-86.28%-476.70%
38
Underperform
$180.48M-50.84%43.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MNPR
Monopar Therapeutics Inc
42.37
38.81
1090.17%
XOMA
Xoma
24.48
0.79
3.33%
CDTX
Cidara Therapeutics
19.15
6.55
51.98%
ANNX
Annexon Biosciences
1.70
-3.40
-66.67%
ITOS
iTeos Therapeutics
6.70
-5.49
-45.04%
CMPX
Compass Therapeutics
1.78
0.19
11.95%

Monopar Therapeutics Inc Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Monopar Therapeutics Appoints Quan Vu as New CFO
Positive
Mar 3, 2025

Monopar Therapeutics Inc. announced the termination of Karthik Radhakrishnan’s employment as Chief Financial Officer, principal financial officer, and principal accounting officer on February 28, 2025. The company’s Board of Directors appointed Quan Vu as the new CFO, effective March 3, 2025. Vu brings extensive experience in corporate and financial strategy, having previously served in various leadership roles in the biopharmaceutical and investment banking sectors. This leadership change is expected to impact Monopar’s financial strategy and operations positively.

Executive/Board Changes
Monopar Therapeutics Appoints Lavina Talukdar to Board
Neutral
Feb 24, 2025

Monopar Therapeutics Inc. announced the resignation of Michael J. Brown from its Board of Directors effective February 19, 2025, and the appointment of Lavina Talukdar to the Board on February 21, 2025. Talukdar, who is currently the Senior Vice President, Head of Investor Relations at Moderna Inc., brings over 20 years of experience in investor relations and healthcare investments. Her appointment is expected to enhance Monopar’s strategic direction and governance, as she will also serve on several key committees within the company.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.